35450-34-1Relevant articles and documents
Single chain white-light-emitting polyfluorene copolymers containing iridium complex coordinated on the main chain
Park, Moo-Jin,Kwak, Jeonghun,Lee, Jonghee,Jung, In Hwan,Kong, Hoyoul,Lee, Changhee,Hwang, Do-Hoon,Shim, Hong-Ku
, p. 1379 - 1386 (2010)
We report the synthesis of single chain white-light-emitting polyfluorene copolymers containing a novel iridium complex with β-diketonate unit, bis(2-benzothiazol-2-yl-N-ethylcarbazole)iridium-l,3bis(p-bromophenyl)l, 3-propanedione ((bec)2IrdbmBr), as the red emission unit. The synthesized polyfluorene copolymers containing the carbazole and iridium complex, poly{9,9-bis(4-octyloxyphenyl)fluorene-2,7-diyl-co(N-hexylcarbazole-3, 6-diyl)-co-[bis(2-benzothiazol-2-yl-N-ethylcarbazole)iridium-l, 3-bis(p-bromophenyl)propanedione-l,3-diyl]} (PFCzIrbecs), were synthesized via palladium-catalyzed Suzuki coupling reactions. These polymers were found to be thermally stable and readily soluble in common organic solvents. Interestingly, the synthesized polymers, PFCzIrbec 05 and PFCzIrbec 2, exhibited two strong emission bands in both the blue and red spectral regions. Light-emitting devices based on these polymers were fabricated in an ITO/PEDOT:PSS/poly(TPD)/polymers/ TPBi/LiF/Al configuration. We obtained white light emission from a single polymer chain by incorporating (bec)2IrdbmBr as the red emission unit into a BOPF and carbazole main chain as the host and blue emission. This device exhibited good performance. In particular, EL device fabricated with PFCzIrbec 2 was found to emit white light consisting of simultaneous blue and red emission with CIE coordinates of (0.31, 0.32), which are close to the standard for white light emission. Moreover, the EL spectrum of PFCzIrbec 2 was stable with respect applied voltage, and CIE coordinates were almost not changed at various driving voltages.
Design, Synthesis, and Pharmacological Characterization of Carbazole Based Dopamine Agonists as Potential Symptomatic and Neuroprotective Therapeutic Agents for Parkinson's Disease
Elmabruk, Asma,Das, Banibrata,Yedlapudi, Deepthi,Xu, Liping,Antonio, Tamara,Reith, Maarten E. A.,Dutta, Aloke K.
, p. 396 - 411 (2019/01/24)
We have developed a series of carbazole-derived compounds based on our hybrid D2/D3 agonist template to design multifunctional compounds for the symptomatic and disease-modifying treatment of Parkinson's disease (PD). The lead molecules (-)-11b (D-636), (-)-15a (D-653), and (-)-15c (D-656) exhibited high affinity for both D2 and D3 receptors and in GTPγS functional assay, the compounds showed potent agonist activity at both D2 and D3 receptors (EC50 (GTPγS); D2 = 48.7 nM, D3 = 0.96 nM for 11b, D2 = 0.87 nM, D3 = 0.23 nM for 15a and D2 = 2.29 nM, D3 = 0.22 nM for 15c). In an animal model of PD, the test compounds exhibited potent in vivo activity in reversing hypolocomotion in reserpinized rats with a long duration of action compared to the reference drug ropinirole. In a cellular antioxidant assay, compounds (-)-11b, (-)-15a, and (-)-15c exhibited potent activity in reducing oxidative stress induced by neurotoxin 6-hydroxydopamine (6-OHDA). Also, in a cell-based PD neuroprotection model, these lead compounds significantly increased cell survival from toxicity of 6-OHDA, thereby producing a neuroprotective effect. Additionally, compounds (-)-11b and (-)-15a inhibited aggregation and reduced toxicity of recombinant alpha synuclein protein in a cell based in vitro assay. These observations suggest that the lead carbazole-based dopamine agonists may be promising multifunctional molecules for a viable symptomatic and disease-modifying therapy of PD and should be further investigated.
COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE DEVICE, ORGANIC ELECTROLUMINESCENCE DEVICE AND ELECTRONIC APPARATUS
-
Paragraph 0290; 0291; 0292; 0306; 0310, (2018/12/11)
A compound represented by the following formula (1):
